RMO No. 25-2020 requires ATRIG applications for VAT-exempt imported prescription drugs and medicines to be processed by the port-of-entry RDO.

Importers of VAT-exempt prescription drugs and medicines must file their Authority to Release Imported Goods applications with the Revenue District Office having jurisdiction over the port of entry, because RMO No. 25-2020 immediately amended the processing office rule under RMO No. 23-2020. For manufacturers, distributors, wholesalers, and retailers bringing in drugs and medicines covered by the Department of Health list of approved drugs and medicines, the practical consequence is clear: the ATRIG process must now be routed through the proper port-of-entry RDO before the imported goods can be released as VAT-exempt goods.

What RMO No. 25-2020 Changed

RMO No. 25-2020 amends certain provisions of RMO No. 23-2020 on the processing and issuance of an Authority to Release Imported Goods, or ATRIG, for Value-Added Tax exemption on the importation of prescription drugs and medicines. The amendment is connected with Revenue Regulations No. 18-2020, which implemented Section 1 of Republic Act No. 11467, further amending Section 109(AA) of the National Internal Revenue Code of 1997, as amended by Republic Act No. 10963, also known as the TRAIN Law.

The most important operational change is the identification of the BIR office that must process the ATRIG. For VAT purposes, the ATRIG shall be issued on all importations of articles exempt from VAT pursuant to RMO No. 35-2002, dated October 28, 2002, at the Revenue District Office having jurisdiction over the port of entry.

RMO No. 25-2020 also provides that, for consistency in the issuance of ATRIG for VAT-exempt transactions, the RDO having jurisdiction over the port of entry shall process applications for ATRIG by manufacturers, distributors, wholesalers, and retailers of drugs and medicines included in the list of approved drugs and medicines issued by the Department of Health.

Who Is Affected by RMO No. 25-2020

The taxpayers most directly affected are manufacturers, distributors, wholesalers, and retailers that import prescription drugs and medicines and seek VAT exemption on those importations. The order is particularly relevant to businesses in the pharmaceutical supply chain, including companies importing medicines for distribution, resale, wholesale supply, or retail sale in the Philippines.

The order also affects customs brokers, tax managers, compliance officers, and corporate accountants handling import documentation for VAT-exempt medicines. In practical terms, the person preparing the ATRIG application must confirm not only whether the imported goods fall within the relevant VAT exemption, but also whether the application is filed with the correct RDO based on the port of entry.

Businesses searching for guidance on BIR ATRIG for VAT-exempt medicines, RMO No. 25-2020 ATRIG port of entry RDO, VAT exemption importation prescription drugs Philippines, DOH approved drugs medicines ATRIG, and RDO jurisdiction over port of entry should treat this issuance as a routing and compliance rule. It does not create a new VAT rate, but it directly affects the process for securing release of imported VAT-exempt goods.

Key Compliance Requirement: File with the RDO Having Jurisdiction Over the Port of Entry

The central compliance requirement under RMO No. 25-2020 is that the ATRIG for VAT-exempt imported prescription drugs and medicines must be processed at the RDO having jurisdiction over the port of entry. This matters because an ATRIG is a release document. If the application is routed to the wrong office, the taxpayer risks delay in processing and release of the imported goods.

The order expressly refers to all importations of articles exempt from VAT pursuant to RMO No. 35-2002. It further states that the policies, guidelines, and procedures set forth in RMO No. 35-2002 shall be strictly followed and observed. Accordingly, taxpayers should not treat RMO No. 25-2020 as a standalone exemption document. It must be read together with the existing ATRIG procedure under RMO No. 35-2002 and the VAT exemption rules implemented through RR No. 18-2020.

The goods must also be drugs and medicines included in the list of approved drugs and medicines issued by the Department of Health. For companies importing prescription medicines, this makes DOH classification and documentation central to the BIR ATRIG process. Before filing, the importer should confirm that the products are covered by the applicable DOH list and that the import documents consistently describe the goods.

Effective Date and Deadline

RMO No. 25-2020 is dated July 24, 2020 and states that it shall take effect immediately. The issuance does not provide a deferred implementation date or a transition period. This means the amended routing rule applies immediately from issuance: the RDO having jurisdiction over the port of entry is the office that processes the ATRIG applications covered by the order.

The order does not state a specific filing deadline measured in days before arrival or release of goods. However, because the ATRIG is connected with the release of imported goods and the recognition of VAT exemption, affected importers should complete the ATRIG application before release is required and should coordinate early with the relevant port-of-entry RDO.

Penalties and Risks for Non-Compliance

RMO No. 25-2020 does not set out a separate schedule of penalties, surcharges, interest, or compromise penalties. It also does not create a new monetary penalty for filing with the wrong RDO. The immediate risk is procedural and commercial: an ATRIG application that is not filed with the proper RDO may result in delay, additional compliance correspondence, or difficulty securing release of goods under VAT-exempt treatment.

For importers of medicines, delay can have business consequences beyond tax administration. It may affect inventory planning, supply commitments, delivery schedules, and documentation with customs brokers and logistics providers. Companies should therefore treat the RDO routing rule as a control point in import compliance, not merely as an internal BIR office instruction.

Practical Steps for Manufacturers, Distributors, Wholesalers, and Retailers

First, identify the port of entry for each shipment of imported prescription drugs or medicines. The relevant processing office under RMO No. 25-2020 is not chosen based on the importer’s head office, principal place of business, or warehouse location. The controlling reference is the Revenue District Office having jurisdiction over the port of entry.

Second, verify whether the imported drugs and medicines are included in the Department of Health list of approved drugs and medicines. The order specifically refers to manufacturers, distributors, wholesalers, and retailers of drugs and medicines included in the DOH list. The tax team should keep the DOH-related product documentation with the import records and ATRIG application file.

Third, align customs, logistics, accounting, and tax documentation. The product description, importer identity, shipment details, and VAT exemption basis should be consistent across the ATRIG application and related import documents. Inconsistent descriptions can create unnecessary questions during processing.

Fourth, follow the policies, guidelines, and procedures under RMO No. 35-2002. RMO No. 25-2020 expressly states that those procedures shall be strictly followed and observed. This means compliance teams should review their existing ATRIG checklist and update the responsible office from any prior internal routing practice to the port-of-entry RDO rule.

Finally, revise internal SOPs for VAT-exempt medicine importations. Pharmaceutical companies and medicine retailers should train their accounting, supply chain, and customs broker teams that ATRIG applications covered by RMO No. 25-2020 must be directed to the RDO with jurisdiction over the port of entry.

Why This Matters for BIR Compliance

RMO No. 25-2020 is short, but it is important because ATRIG processing is a practical gatekeeper for VAT-exempt importations. A company may have a valid substantive position that the medicines are VAT-exempt, but release and documentation may still be affected if the ATRIG application is not handled by the correct BIR office.

For businesses importing prescription drugs and medicines, the key takeaway is simple: confirm DOH coverage, identify the port of entry, file the ATRIG application with the RDO having jurisdiction over that port, and follow RMO No. 35-2002 procedures strictly. These steps should be completed before the shipment becomes urgent for release.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists businesses, importers, pharmaceutical companies, distributors, retailers, and corporate tax teams in navigating BIR compliance requirements, including VAT exemption issues, ATRIG applications, import documentation, and tax risk review. For companies dealing with VAT-exempt importation of prescription drugs and medicines, early legal and tax review can help avoid release delays, documentation gaps, and preventable disputes with revenue offices.

For assistance with RMO No. 25-2020 compliance, ATRIG processing, VAT-exempt importation of medicines, or broader BIR tax advisory needs, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *